Phathom Pharmaceuticals, Inc. (PHAT)
NASDAQ: PHAT · Real-Time Price · USD
6.96
0.00 (0.00%)
At close: Jan 17, 2025, 4:00 PM
6.88
-0.08 (-1.15%)
Pre-market: Jan 21, 2025, 8:25 AM EST
Phathom Pharmaceuticals Revenue
Phathom Pharmaceuticals had revenue of $16.35M in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $26.27M. In the year 2023, Phathom Pharmaceuticals had annual revenue of $682.00K.
Revenue (ttm)
$26.27M
Revenue Growth
n/a
P/S Ratio
15.83
Revenue / Employee
$58,119
Employees
452
Market Cap
475.91M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
PHAT News
- 5 weeks ago - Phathom Pharmaceuticals Submits Citizen Petition to FDA Seeking Correction of Orange Book Listings for VOQUEZNA® (vonoprazan) Tablets - GlobeNewsWire
- 2 months ago - Phathom Pharmaceuticals, Inc. (PHAT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 7, 2024 - GlobeNewsWire
- 3 months ago - Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting - GlobeNewsWire
- 5 months ago - Phathom Pharmaceuticals Announces Pricing of $130 Million Offering of Common Stock and Pre-Funded Warrants - GlobeNewsWire
- 5 months ago - Phathom Pharmaceuticals, Inc. (PHAT) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 5 months ago - Phathom Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire